Reference

1. Alvin CP, Braunwald E, Faucei AS, Kasper DL, Hauser SL, Longo DL, Larry JJ (2001), Diabetes Mellitus, Harrison's principles of internal medicine, 15th edn, McGraw Hill Medical Publishing division, New York., pp 2109–2137.
2. American Diabetes Association (2010), Standards of medical care in diabetes, Diabetes Care, 33., S11–61.
3. Ardawi MS, Jamal YS. (1990), Glutamine metabolism in skeletal muscle of glucocorticoid-treated rats, Clin Sci (Lond) Aug,79(2).,139–147.
4. Bello- Sani D, Bakari AG, Anumah FE(2007), Dyslipidaemia in person with type 2 diabetes mellitus in Kaduna, Nigeria. Int J Diabetes and Metabolism,15.,9-13.
5. Brohi K, Singh J, Heron M, Coats T (2003), Acute traumatic coagulopathy, J Trauma ,54.,1127–30.
6. Diabetes Care(2013), Jan, 36(1)., S11-S66.
7. Dunn EJ, Arians RA, de Lange M, Snieder H, Turney JH, Spector TD, Grant PJ (2004), Genetics of fibrin clot structure, a twin study, Blood, 103., 1735–1740.
8. Ernst E (1991), Fibrinogen, An independent risk factor for cardiovascular disease, Br Med

9. Ernst E, Ludwig KR (1993), Fibrinogen as a cardiovascular risk factor, a meta-analysis and review of literature, Ann Intern Med 118.,956–963
10. Everse SJ, Spraggon G, Veerapandian L, Reily M, Doolitle RF (June 1998), "Crystal structure of fragment double-D from human fibrin with two different bound ligands", Biochemistry, 37 (24)., 8637-42.
11. Feo De P, Gan Gaisano M, Haymond MW (1991), Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans, J Clin Invest, 88., 833–840.
12. Festa A, D' Agostino R Jr. Tracy RP, Haffner Sm (2002), The Insulin Resistance Atherosclerosis study: elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes, The insulin resistance atherosclerosis study, Diabetes 51.,1131-1137.

13. Folsom AR, Wu KK, Davis CE, Conlan M G, Sorlie P D, Szklo M (1991), Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors, Atherosclerosis, 91., 191-205.
14. Ganda OP and Arkin CF (1992), Hyperfibrinogenemia, An important risk factor for vascular complications in diabetes, Diabetes Care, 15., 1245–1250.
15. Guardado-Mendoza R, Jimenez-Ceja L, Pacheco-Carrasco MF (2009), Fibrinogen is associated with silent myocardial ischaemia in type 2 diabetes mellitus, Acta Cardiologica,64(4).,523–530.
16. HealthInstitute (2009), Types of diabetes. [Internet], Available at http://www.healthinsite.gov.au/topics., Types of diabetes.
17. Joslin's (1994), Diabetes Mellitus, 13th edition, Lea and Febriger, A Waverly Company.,
18. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR (1990), Diabetes, fibrinogen and risk of cardiovascular disease, the Framingham experience, Am Heart J, 120.,672–676.
19. Khawand El, C, J. Jamart, J. Donckier, B. Chatelain, E. Lavenne, M. Moriau and M. Buysschaert (1993), Hemostasis variables in type I diabetic patients without demonstrable vascular complications, Diabetes Care, 16., 1137-1145.
20. Laakso M and Letho S (1997) Epidemiology of macrovascular disease in diabetes, Diabetes reviews,5.,294-315.
21. Mansfield MW and Grant PJ(1995), Fibrinolysis and diabetic retinopathy in NIDDM, Diabetes Care,18.,1577–1581.
22. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM(2000), Hyperinsulinemia, hyper- Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study, JAMA 283., 221–228.
23. Missov RM, Stolk RP, van der Bom JG, (1996), Plasma fibrinogen in NIDDM, The Rotterdam Study, Diabetes Care, 19.,157–159.
24. O'Riordain MG, Ross Ja, Fearon KCH, Mainray J, Farouk M, Garden J, Carter DC, (1995) Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes, Am J Physiol 269.,E323-E330.

25. Pickup JC, Mattock MB, Chusney GD, Burt D(1997), NIDDM as a disease of the innate immune system, association of acute-phase reactants and interleukin-6 with metabolic syndrome

26. Rodrigues TC,Snell-Bergeon JK, Maahs DM, Kinney GL, Rewers M (2010), Higher fibrinogen levels predict progression of coronary artery calcification in adults with type 1 diabetes. Atherosclerosis 210.,671–673.

27. Rother KI, (2007), Diabetes treatment, bridging the divide, The New England Journal of Medicine, 356., (15), 1499-501.

28. Shmidt MI, Duncan BB, Sherrett Ar, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G (1999), Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study), a cohort study ,Lancet 353.,1649-1652.

29. Shoback, edited by David G. Gardner, Dolores (2011), "Chapter 17",Greenspan's basic and clinical endocrinology, 9th ed., New York.

30. Thomson FJ, Masson EA, Leeming JT, Boultan AJM (1991), Lack of Knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing ,20.,404-6.

31. Wild S, Roiglic G, Grren A, Sicree R, King H(2009), Global Prevalence of Diabetes, Diabetes Care, 27.,1047-53.

32. Yarnell JW, Baker IA, Sweetnam PM, (1991), Fibrinogen, viscosity and white cell count are major risk factors for ischemic heart disease, The Caerphilly and Speedwell collaborative heart disease studies, Circulation, 83.,836–844.